UNLABELLED: Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate improved adherence, with new chemical entities to be used in the management of osteoporosis. INTRODUCTION: Several medications have been unequivocally shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients. METHODS: An extensive search of Medline from 1985 to 2006 retrieved all trials including the keywords osteoporosis, compliance, persistence or adherence followed by a critical appraisal of the data obtained through a consensus expert meeting. RESULTS: The impact of non-adherence on the clinical development of interventions is reviewed, so that clinicians, regulatory agencies and reimbursement agencies might be better informed of the problem, in order to stimulate the necessary research to document adherence. CONCLUSION: Adherence to therapy is a major problem in the treatment of osteoporosis. Both patients and medication factors are involved. Adherence studies are an important aspect of outcomes studies, but study methodologies are not well developed at the moment and should be improved. Performing adherence studies will be stimulated when registration authorities accept the result of these studies and include the relevant information in Sect. 5.1 of the summary of product characteristics. Reimbursement authorities might also consider such studies as important information for decisions on reimbursement.
UNLABELLED: Adherence to anti-osteoporosis medications is currently low and is associated with poor anti-fracture efficacy. This manuscript reviews the potential design of clinical studies that aim to demonstrate improved adherence, with new chemical entities to be used in the management of osteoporosis. INTRODUCTION: Several medications have been unequivocally shown to decrease fracture rates in clinical trials. However, in real life settings, long-term persistence and compliance to anti-osteoporosis medication is poor, hence decreasing the clinical benefits for patients. METHODS: An extensive search of Medline from 1985 to 2006 retrieved all trials including the keywords osteoporosis, compliance, persistence or adherence followed by a critical appraisal of the data obtained through a consensus expert meeting. RESULTS: The impact of non-adherence on the clinical development of interventions is reviewed, so that clinicians, regulatory agencies and reimbursement agencies might be better informed of the problem, in order to stimulate the necessary research to document adherence. CONCLUSION: Adherence to therapy is a major problem in the treatment of osteoporosis. Both patients and medication factors are involved. Adherence studies are an important aspect of outcomes studies, but study methodologies are not well developed at the moment and should be improved. Performing adherence studies will be stimulated when registration authorities accept the result of these studies and include the relevant information in Sect. 5.1 of the summary of product characteristics. Reimbursement authorities might also consider such studies as important information for decisions on reimbursement.
Authors: Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart Journal: Arch Intern Med Date: 2005-11-14
Authors: J Y Lee; J W Kusek; P G Greene; S Bernhard; K Norris; D Smith; B Wilkening; J T Wright Journal: Am J Hypertens Date: 1996-08 Impact factor: 2.689
Authors: Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick Journal: Osteoporos Int Date: 2003-09-19 Impact factor: 4.507
Authors: Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger Journal: Am J Med Date: 2003-08-15 Impact factor: 4.965
Authors: Carmen Turbí; Gabriel Herrero-Beaumont; Juan Carlos Acebes; Antonio Torrijos; Jenaro Graña; Roberto Miguélez; JoséAntonio Sacristán; Fernando Marín Journal: Clin Ther Date: 2004-02 Impact factor: 3.393
Authors: O Bruyere; J A Kanis; M-E Ibar-Abadie; N Alsayed; M L Brandi; N Burlet; D L Cahall; A Chines; J-P Devogelaer; W Dere; N Goel; N Hughes; J-M Kaufman; S Korte; B H Mitlak; D Niese; R Rizzoli; L C Rovati; J-Y Reginster Journal: Osteoporos Int Date: 2010-03-18 Impact factor: 4.507
Authors: J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli Journal: Osteoporos Int Date: 2008-02-12 Impact factor: 4.507
Authors: Debby den Uyl; Piet P M M Geusens; Frank N R van Berkum; Harry H M L Houben; Max C Jebbink; Willem F Lems Journal: Clin Rheumatol Date: 2009-12-22 Impact factor: 2.980